Wolverine Asset Management LLC Acquires New Holdings in Kenvue Inc. $KVUE

Key Points

• Wolverine Asset Management acquired a new stake of 142,878 shares (~$2.47M) in Kenvue in Q4, joining other large institutional buyers and leaving institutional ownership at 97.64%.
• Kenvue beat quarterly estimates with $0.27 EPS and $3.78B revenue, has a market cap near $32.9B, and declared a quarterly dividend of $0.2075 (4.8% yield) despite a payout ratio above 100%.
• Analysts maintain a consensus "Hold" rating with a consensus price target of $19.33, and several firms have recently lowered price targets or downgraded the stock.

Wolverine Asset Management LLC acquired a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 142,878 shares of the company's stock, valued at approximately $2,465,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in KVUE. Van ECK Associates Corp lifted its stake in Kenvue by 101.3% in the 3rd quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company's stock valued at $298,008,000 after purchasing an additional 9,240,434 shares during the last quarter. American Century Companies Inc. lifted its stake in Kenvue by 22.4% in the 3rd quarter. American Century Companies Inc. now owns 37,046,660 shares of the company's stock valued at $601,267,000 after purchasing an additional 6,781,640 shares during the last quarter. Mondrian Investment Partners LTD bought a new position in Kenvue in the 3rd quarter valued at approximately $79,269,000. Alliancebernstein L.P. lifted its stake in Kenvue by 115.9% in the 2nd quarter. Alliancebernstein L.P. now owns 6,438,473 shares of the company's stock valued at $134,757,000 after purchasing an additional 3,456,204 shares during the last quarter. Finally, Amundi lifted its stake in Kenvue by 21.6% in the 3rd quarter. Amundi now owns 17,645,761 shares of the company's stock valued at $277,012,000 after purchasing an additional 3,135,871 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

KVUE stock opened at $17.15 on Tuesday. The company has a fifty day moving average price of $17.72 and a 200-day moving average price of $17.19. The company has a market capitalization of $32.92 billion, a P/E ratio of 22.27, a PEG ratio of 3.96 and a beta of 0.55. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.05. The firm had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The company's revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.26 earnings per share. As a group, equities analysts expect that Kenvue Inc. will post 1.1 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th will be paid a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. Kenvue's dividend payout ratio (DPR) is presently 107.79%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on KVUE shares. Weiss Ratings reissued a "hold (c-)" rating on shares of Kenvue in a research note on Wednesday, April 8th. Argus upgraded shares of Kenvue to a "hold" rating in a research report on Friday, March 6th. Barclays dropped their price target on shares of Kenvue from $19.00 to $18.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 14th. UBS Group dropped their price target on shares of Kenvue from $19.00 to $18.00 and set a "neutral" rating for the company in a research note on Tuesday, April 7th. Finally, Jefferies Financial Group downgraded shares of Kenvue from a "buy" rating to a "hold" rating and dropped their price target for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Three investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.